Eli Lilly and Company funded the study, which was designed by Versanis Bio, a wholly owned subsidiary of Eli Lilly and Company
Yang, F., Luo, X., Li, J., Lei, Y., Zeng, F., Huang, X., Lan, Y., & Liu, R
& Stone, T
With the rapidly increasing use of semaglutides in our country, we know some patients who present with NAION will be on this drug, and to add to the challenge, diabetes, hypertension, cardiovascular disease and obesity, the common indications for prescribing a semaglutide, are also risk factors for NAION
Every cell in your body requires glucose for energy, yet too much glucose circulating in your bloodstream causes progressive damage to blood vessels, nerves, and organs over time
Some programs start with a lower introductory rate, then increaseso its worth understanding the long-term cost upfront